Company Overview of Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. provides human prescription medicines. It offers pharmaceutical products for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. Its products include angiotensin II receptor blocker Micardis tablets for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients who are unable to take angiotensin-converting enzyme inhibitors; and COMBIVENT RESPIMAT, an inhaler for patients with chronic obstructive pulmonary disease. The company’s products also comprise Flibanserin for the treatment of hypoactive sexual desire disorder in pre-menopausal women; SPIRIVA Ha...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1971
Key Executives for Boehringer Ingelheim Pharmaceuticals, Inc.
Director of Office of Diversity and Inclusion
Manager of Communications and Public Relations
Compensation as of Fiscal Year 2015.
Boehringer Ingelheim Pharmaceuticals, Inc. Key Developments
Boehringer Ingelheim Presents New Praxbind® Analyses on Reintroduction of Antithrombotic Therapy After Reversal of Dabigatran
Nov 9 15
Boehringer Ingelheim announced results from two new analyses evaluating idarucizumab, recently approved under the Accelerated Approval pathway and marketed in the U.S. as Praxbind®, a specific reversal agent for Pradaxa® (dabigatran etexilate mesylate), that were presented at the American Heart Association (AHA) Scientific Sessions 2015 in Orlando. The analysis examined reinitiation of antithrombotic therapy after administration of idarucizumab. The reinitiation of antithrombotic therapy in patients with nonvalvular atrial fibrillation (NVAF) is important in order to address the underlying risk of stroke. An interim analysis of data from the ongoing phase III RE-VERSE AD™ trial showed reinitiation of alternative antithrombotic therapy was possible any time after idarucizumab use. Reinitiation of alternative antithrombotic therapy (e.g. heparin) after treatment with idarucizumab ranged from 0.2 days to 77.2 days in patients who presented with uncontrolled or life-threatening bleeding and 0 days to 40.8 days in patients requiring emergency surgery or an urgent procedure. Reinitiation of PRADAXA after treatment with idarucizumab ranged from 1.3 days to 90.6 days in patients with uncontrolled or life-threatening bleeding, and 1 day to 63.31 days in patients requiring emergency surgery or an urgent procedure. A second presentation on idarucizumab included findings from an in vitro study investigating the efficacy of idarucizumab in the presence of coagulation factor concentrates [e.g., blood-clotting proteins recombinant Factor VIIa, 3- or 4-factor prothrombin complex concentrates (PCC), and activated PCC]. The results suggest that the use of idarucizumab did not inhibit the anticoagulation effects of other commercially available blood thinners (direct factor Xa inhibitors, heparins, or other direct thrombin inhibitors). The study also showed that the reversal effect of idarucizumab on dabigatran was not affected by the presence of coagulation factor concentrates. This result is important as these agents are frequently used in the management of patients presenting with acute hemorrhages.
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Presentation of Several New Post-Hoc Analyses from the Tonado 1&2 and Otemto 1&2 Studies at American College of Chest Physicians Annual Meeting (Chest 2015) in Montreal
Oct 27 15
Boehringer Ingelheim Pharmaceuticals, Inc. announced the presentation of several new post-hoc analyses from the TONADO 1&2 and OTEMTO 1&2 studies at the American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal. One analysis showed significant lung function improvement, as measured by FEV1 AUC0 "3, with once daily STIOLTO RESPIMAT across a range of age groups of COPD patients (adult patients less than 65 years, 65- less than 75 years, 75- less than 85 years and greater than or equal to 85 years). In addition, there were two analyses which showed treatment with STIOLTO RESPIMAT reduced the frequency of night-time rescue medication use, as measured by puffs needed per night, and improved the score of Transition Dyspnea Index (TDI), which is a measure of severity of shortness of breath, in COPD patients, compared to tiotropium, olodaterol or placebo. STIOLTO RESPIMAT was approved in May 2015 for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is not indicated to treat asthma or acute deterioration of COPD. Long-acting beta2-adrenergic agonists, such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma-related death. STIOLTO RESPIMAT is not indicated for asthma and should not be initiated in acutely deteriorating COPD patients or for the relief of acute symptoms. STIOLTO RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product. As with other inhaled medicines, STIOLTO RESPIMAT may cause paradoxical bronchospasm, which means breathing or wheezing worsen, that may be life-threatening. The most common adverse reactions were nasopharyngitis (common cold), cough and back pain. Key findings include: In the subgroup analysis of the replicate, double-blind, parallel-group 52 week TONADO 1&2 (NCT01431274 /NCT01431287) and 12 week OTEMTO® 1&2 (NCT01964352 /NCT02006732) studies, once-daily STIOLTO RESPIMAT increased FEV1 AUC0-3, a key measure of lung function, across a range of adult COPD patients, compared to tiotropium, olodaterol or placebo. Adjusted mean results were consistent between studies: [Abstract 740A]; T+O 5/5 µg: 0.120 L and 0.151 L in patients; T+O 5/5 µg: 0.116 L (P=0.0003) and 0.376 L p T+O 5/5 µg: 0.094 L (P=0.004) and 0.322 L (p)· In a post-hoc analysis of the TONADO® 1&2 and OTEMTO® 1&2 studies, treatment with once-daily STIOLTO RESPIMAT significantly reduced night-time rescue medication use compared to tiotropium, olodaterol or placebo At week 52: -0.55 puffs/night for T+O 5/5 µg versus T 5 µg (pAbout the RESPIMAT® Inhaler The RESPIMAT is the platform inhaler for the Boehringer Ingelheim respiratory therapies. Only the RESPIMAT inhaler actively delivers a slow-moving mist that helps patients inhale the medication. The RESPIMAT inhaler delivers medication independent of inspiratory effort. As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as coordination between actuation of the inhaler and inspiration through the delivery system. The duration of inhalation should be at least as long as the spray duration (1.5 seconds).
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Initial Results from a Patient Registry Reveal Insights About Idiopathic Pulmonary Fibrosis (IPF)
Oct 22 15
Boehringer Ingelheim Pharmaceuticals, Inc. announced initial results of the first 49 people enrolled in the IPF-PRO Registry, which shed light on characteristics of people with IPF at the time of diagnosis. Results will be presented at the American College of Chest Physicians Annual Meeting (CHEST 2015) on October 26 in Montreal, Canada. From an evaluation of the first 49 people with IPF enrolled in the registry (NCT01915511; abstract 362A), the results showed: Most people exhibited symptoms of IPF for more than a year before being diagnosed; By the time of enrollment, many people exhibited considerably impaired lung function, with a median forced vital capacity (FVC, or the amount of air that can be exhaled after maximum inhalation) of 72%(61% to 81%) predicted and diffusing capacity of carbon monoxide (DLCO, or the measure of the lungs' ability to transfer oxygen to red blood cells) of 39% (34 to 48%) predicted; 29% (14 patients) required supplemental oxygen when resting, and 45% (22 patients) required supplemental oxygen during activities; Nearly all patients (98%, 48 patients) received an imaging test known as high resolution CT scan as part of their diagnosis, while 20% (10 patients) also underwent surgical biopsy to examine for signs of IPF; and The most commonly reported comorbidities were gastroesophageal reflux disease (GERD) (69%), coronary artery disease (31%) and sleep apnea (29%).
Similar Private Companies By Industry
Recent Private Companies Transactions